0
0
A comprehensive study has unveiled a potential correlation between individuals with blood group O and an increased risk of cerebral venous thrombosis (CVT), commonly known as venous stroke, subsequent to receiving the Oxford-AstraZeneca vaccine, also administered as Covishield in India.
The study, published in the Journal of the Royal Society of Medicine, encompassed 523 patients diagnosed with CVT, of which 82 individuals experienced this condition after receiving the Oxford-AstraZeneca vaccine, while the remaining 441 were unvaccinated CVT patients. The 28-day period after vaccine administration was considered the crucial window to attribute any CVT occurrence to the vaccine.
Researchers meticulously analyzed the blood groups of the participants to discern the distribution among vaccinated and unvaccinated CVT patients. Strikingly, the study found a higher prevalence of blood group O among individuals who encountered a venous stroke after receiving the Oxford-AstraZeneca vaccine, standing at 43%, compared to 17% among unvaccinated CVT patients.
Contrastingly, individuals with blood group A were more predominant (71%) among the unvaccinated group, regardless of established CVT risk factors like gender.
Professor Pankaj Sharma from the Department of Biological Sciences at Royal Holloway, University of London, highlighted the potential implications of these findings. “Our research hints at the possibility of predicting those at a higher risk of cerebral venous thrombosis stroke post Covid-19 vaccination through a simple blood group test,” Sharma stated.
Sharma further emphasized that individuals with blood group O appear to be two-and-a-half times more likely to fall into the category at risk after vaccination. This insight might offer governments a means to forecast individuals more susceptible to stroke post-vaccination, particularly in regions with financial constraints, where cost-effective and easily transportable vaccines might prove more beneficial.
The study’s revelations, if validated through further research, could significantly aid in identifying individuals with higher susceptibility to venous strokes post-Oxford-AstraZeneca vaccination, potentially guiding vaccination strategies and ensuring safer vaccine deployment.
